IDH1 and glioblastoma: A new diagnostic paradigm emerged in 2009 when mutations in the cytosolic isocitrate dehydrogenase 1 (IDH1) enzyme were detected in 70–80% of grade II, III and grade IV secondary (upgraded) GBMs, but rarely in primary GBM tumors [1].